Silver Book Fact

A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.

Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Arch Neurol. 2005; 62(2): 241-8. http://archneur.ama-assn.org/cgi/content/full/62/2/241

Reference

Title
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Publication
Arch Neurol
Publication Date
2005
Authors
Parkinson Study Group
Volume & Issue
Volume 62, Issue 2
Pages
241-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Medicaid Costs, 5-Year Delayed Onset  
  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.  
  • More Effective Treatment of Alzheimer’s Disease Could Save Billions: Combined Medicare and Medicaid savings from effective treatment of Alzheimer’s diease  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.